B. Riley initiated coverage on shares of Oncology Institute (NASDAQ:TOI - Free Report) in a research report report published on Wednesday, MarketBeat reports. The firm issued a buy rating and a $6.00 price target on the stock. B. Riley also issued estimates for Oncology Institute's Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.55) EPS and FY2025 earnings at ($0.55) EPS.
Separately, BTIG Research began coverage on shares of Oncology Institute in a report on Thursday, May 15th. They issued a "buy" rating and a $7.00 target price on the stock.
View Our Latest Research Report on Oncology Institute
Oncology Institute Price Performance
TOI stock traded down $0.15 during mid-day trading on Wednesday, hitting $3.50. The company had a trading volume of 1,395,441 shares, compared to its average volume of 1,217,780. The company has a market capitalization of $312.66 million, a price-to-earnings ratio of -4.97 and a beta of 0.02. Oncology Institute has a 12-month low of $0.13 and a 12-month high of $3.83. The company has a quick ratio of 1.59, a current ratio of 1.79 and a debt-to-equity ratio of 14.58. The company has a 50-day moving average price of $2.73 and a 200 day moving average price of $1.73.
Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. The company had revenue of $104.41 million during the quarter. Oncology Institute had a negative return on equity of 445.02% and a negative net margin of 15.38%.
Insider Buying and Selling
In other news, Director Brad Hively sold 1,976,137 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total value of $5,671,513.19. Following the sale, the director owned 603,501 shares in the company, valued at $1,732,047.87. This represents a 76.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Growth I. L.P. M33 sold 76,324 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $3.05, for a total transaction of $232,788.20. Following the completion of the sale, the director owned 1,272,724 shares in the company, valued at $3,881,808.20. The trade was a 5.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,726,137 shares of company stock valued at $13,379,013 in the last three months. 8.50% of the stock is currently owned by corporate insiders.
Institutional Trading of Oncology Institute
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC grew its position in Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after buying an additional 109,769 shares during the period. Virtu Financial LLC acquired a new stake in Oncology Institute during the fourth quarter valued at $41,000. Renaissance Technologies LLC grew its position in Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after buying an additional 12,000 shares during the period. XTX Topco Ltd grew its position in Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock valued at $63,000 after buying an additional 18,448 shares during the period. Finally, Citizens Financial Group Inc. RI acquired a new stake in Oncology Institute during the first quarter valued at $71,000. Institutional investors and hedge funds own 36.86% of the company's stock.
Oncology Institute Company Profile
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
Read More
Before you consider Oncology Institute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.
While Oncology Institute currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
